Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.05
-$0.07-6.25%
NASDAQ
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -48.90% | 1,220.83% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -48.90% | 1,220.83% | |||
| Cost of Revenue | 20.73% | 20.98% | |||
| Gross Profit | -22.28% | -18.58% | |||
| SG&A Expenses | 7.40% | 56.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.75% | 42.97% | |||
| Operating Income | -12.19% | -42.06% | |||
| Income Before Tax | -12.52% | -40.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.52% | -40.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.52% | -40.62% | |||
| EBIT | -12.19% | -42.06% | |||
| EBITDA | -12.21% | -42.11% | |||
| EPS Basic | 5.93% | -29.76% | |||
| Normalized Basic EPS | 5.91% | -29.73% | |||
| EPS Diluted | 5.93% | -29.76% | |||
| Normalized Diluted EPS | 5.91% | -29.73% | |||
| Average Basic Shares Outstanding | 19.60% | 8.34% | |||
| Average Diluted Shares Outstanding | 19.60% | 8.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||